C

코오롱티슈진

950160KOSDAQ기초 의약물질 제조업

42.9 / 100

Reference Date: 2026-07-24

Financial Score18.0 / 40
News Sentiment17.9 / 25
Momentum6.0 / 20
Disclosure1.0 / 15
AI Analysis: the debt ratio is low with sound financial health but ROE is below the industry average. Plunged 79.2% over the past month, and news sentiment is negative.

Company InformationBased on 2025 Annual Report

Business Overview

Koongtishujin is a biotech company developing cell gene therapy drugs using its TG-C platform, currently conducting Phase III clinical trials for knee osteoarthritis and Phase II trials for hip osteoarthritis. As of July 2024, the Phase III trial for knee osteoarthritis has enrolled 1,066 patients. The company also operates a complex distribution business, selling health supplements, cosmetics, and wines through its W-store and L&B segments.

Number of Employees

58people

Average Salary

163.1M KRW

Score Calculation Basis

Detailed Financial Score

PER
Industry Average 25.444.0Point
PBR
Industry Average 1.263.5Point
ROE
-188.19Industry Average -6.033.5Point

31.2x industry avg (excellent)

Debt Ratio
6.60Industry Average 6.624.0Point

In line with industry avg

Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.3% (2-year basis)

Operating Profit Growth Rate
0.5 / 3

Avg ▼0.0% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -77.0% (declining, 3yr)

Detailed News Sentiment

17 totalPositive 3Neutral 2Negative 12Average Sentiment Score 71.8

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 21,050Won52-week high 138,80052-week low 21,050
1-month return0.0Point

1m -79.18% (strong drop)

Volume trend5.0Point

Volume increasing

Detailed Disclosure

4 totalPositive 0Neutral 1Negative 3
  • Neutral투자판단관련주요경영사항(임상시험결과) (TGC 15302 Study 탑라인 데이터 )2026-07-20
  • Negative[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)2026-07-09
  • Negative소송등의판결ㆍ결정(일정금액이상의청구)2026-07-03
  • Negative[기재정정]소송등의제기ㆍ신청(일정금액이상의청구)2026-07-01